saxagliptin reduced protein kinase C-mediated delayed rectifier K + current that prolonged action potential duration and consequently QTc interval. Importantly, saxagliptin aggravated pre-existing cardiac dysfunction induced by ischemia/reperfusion injury. In conclusion, our novel results provide mechanisms for the off-target deleterious effects of saxagliptin on cardiac function and support the outcome of SAVOR-TIMI 53 trial that linked saxagliptin with the risk of heart failure.
a b s t r a c t
Saxagliptin treatment has been associated with increased rate of hospitalization for heart failure in type 2 diabetic patients, though the underlying mechanism(s) remain elusive. To address this, we assessed the effects of saxagliptin on human atrial trabeculae, guinea pig hearts and cardiomyocytes. We found that the primary target of saxagliptin, dipeptidyl peptidase-4, is absent in cardiomyocytes, yet saxagliptin internalized into cardiomyocytes and impaired cardiac contractility via inhibition of the Ca 2+ /calmodulin-dependent protein kinase II-phospholamban-sarcoplasmic reticulum Ca 2+ -ATPase 2a axis and Na + -Ca 2+ exchanger function in Ca 2+ extrusion. This resulted in reduced sarcoplasmic reticulum Ca 2+ content, diastolic Ca 2+ overload, systolic dysfunction and impaired contractile force. Furthermore, saxagliptin reduced protein kinase C-mediated delayed rectifier K + current that prolonged action potential duration and consequently QTc interval. Importantly, saxagliptin aggravated pre-existing cardiac dysfunction induced by ischemia/reperfusion injury. In conclusion, our novel results provide mechanisms for the off-target deleterious effects of saxagliptin on cardiac function and support the outcome of SAVOR-TIMI 53 trial that linked saxagliptin with the risk of heart failure. Ó 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The prevalence of diabetes mellitus is on rise and estimated to affect 642 million people worldwide by 2040 [1] . Approximately 90% of diabetic patients suffer from type 2 diabetes [1] . Diabetes is associated with various micro-and macro-vascular complications including peripheral vascular disease, stroke and coronary heart disease [2] . On a long run, these complications may favor diabetic cardiomyopathy and in turn lead to heart failure (HF) [3] , which is one of the major causes of morbidity and mortality in type 2 diabetic patients [4] .
Though the exact pathophysiological relationship between HF and diabetes is multifactorial and not completely understood, both diseases share common etio-pathological factors such as metabolic disturbances, oxidative stress, impaired Ca 2+ -homeostasis and electrophysiological alterations [5, 6] . in the failing heart, irrespective of diabetes, is impaired diastolic function noticeable as delayed cardiac relaxation [7] . This alteration often precedes reduction in ejection fraction as a sign of systolic dysfunction [7, 8] . Moreover, diabetic cardiomyopathy is manifested by impaired relaxation [9] with diastolic and systolic dysfunction [10] . In addition, electrophysiological alterations are commonly observed in the failing heart. Of note, prolonged action potential duration favoring arrhythmia is considered a hallmark of HF [11] . Treatment of type 2 diabetic patients with some oral antihyperglycemic drugs, such as thiazolidinediones, has been associated with an increased risk of HF [12] . Therefore, in type 2 diabetes, the risk of HF has become an essential cardiovascular safety parameter for newer anti-hyperglycemic agents including gliptins, the inhibitors of dipeptidyl peptidase-4 (DPP-4). Over the last decade, gliptins have become frequently used oral anti-hyperglycemic agents due to effective glucose lowering potential and low risk profile [13] . Gliptins inhibit DPP-4-mediated degradation of glucagon like peptide-1 (GLP-1) that augments prandial insulin secretion from pancreatic beta cells and reduces glucagon secretion from pancreatic alpha cells. This phenomenon is commonly known as the incretin effect [14] .
The TECOS trial investigating cardiovascular safety of sitagliptin showed no increase in the risk of HF [15] . However, alogliptin treatment was associated with a numerical increase in the rate of hospitalization for HF in the EXAMINE trial, albeit not statistically significant [16] . Meanwhile, an unexpected yet substantial 27% increase in the rate of hospitalization for HF in type 2 diabetic patients receiving saxagliptin in the SAVOR-TIMI 53 trial was clinically alarming [17] . Thus, the U.S. FDA issued a warning on saxagliptin treatment and the risk of HF in early 2016 [18] .
To date, there is no information available on the effects of saxagliptin on cardiac contractility and/or electrophysiology that might reveal potential mechanistic link(s) between saxagliptin treatment and HF. Therefore, this study was designed to evaluate the acute and direct effects of saxagliptin on cardiac contractility and electrophysiology at molecular, cellular, tissue and organ levels. Compared to in vivo animal studies, this approach avoids secondary effects on tissue metabolism due to elevated circulating GLP-1.
Methods

Materials
Unless specified, materials were purchased from Sigma-Aldrich, MO, USA.
Human right atrial appendages (RAA)
The use of human tissue was approved by the ethics committee of the Medical University of Graz, Austria (19-109 ex 07/08) and all patients gave informed written consent according to the WMA Declaration of Helsinki, 2013. RAA were obtained from 13 patients undergoing cardiac surgery. Information about patients, diseases and drug therapy is given in Table 1 .
Animals
The experimental procedure and number of used animals were approved by the ethics committee of the Federal Ministry of 
Culture of HL-1 cells
HL-1 cells (a murine atrial cell line, passage 15, kindly provided by Dr. W. C. Claycomb, Louisiana State University Health Science Center, New Orleans, LA, USA) were cultured in fibronectin (0.5%, w/v)/gelatin (0.02%, w/v) coated flasks and maintained in Claycomb medium (Sigma-Aldrich, Vienna, Austria) containing 10% (v/v) fetal bovine serum, 0.1 mM norepinephrine, 2 mM Lglutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin, and kept at 37°C under 5% CO 2 , as previously described [19] .
Excitation-contraction coupling of human RAA trabeculae
RAA samples were transported in a cold modified-Tyrode's solution (composition in mM: NaCl 127, KCl 2.3, CaCl 2 0.2, MgSO 4 0.6, NaHCO 3 25, KH 2 PO 4 1.3, D(+)-glucose 11.2, insulin 5 IU/l, pH 7.4 adjusted with NaOH) containing 2,3-butanedione 2-monoxime (5 mM). Trabeculae (muscle strips with a crosssectional area of <0.6 mm 2 ) were isolated and mounted on miniature hooks connected to a force transducer (Scientific Instruments, CA, USA) as previously described [20, 21] . Electrical stimulation (1 Hz, voltage 25% over threshold) was induced by a stimulator (STM1, Scientific Instruments). After a gradual increase in Ca 2+ concentration (200 mM to 2.5 mM) trabeculae were stretched stepwise to reach an optimum preload level (baseline). After baseline recording trabeculae were perfused with modified-Tyrode alone (rundown) or containing indicated concentrations of saxagliptin (Adooq Bioscience) for indicated times and stimulated at 1 Hz frequency. Data were stored digitally (Labview, Adooq Bioscience) and analogously using a thermorecorder (Graphtec Linearcorder WR 3320, Graphtec, CA, USA). RAA trabeculae developed force was calculated as systolic force minus diastolic force at indicated time points and normalized to baseline values, as previously described [22] . The rate of contraction-force fall (dF/dt min ) was calculated at indicated time points and normalized to baseline values. [23] . Aortas were cannulated, mounted on a Langendorff perfusion setup and perfused with oxygenated KrebsHenseleit solution at a constant flow rate of 10 ml/min/g wet weight. A fluid-filled balloon was inserted into the left ventricle (LV) and connected to a pressure transducer. After baseline equilibration (30 min) hearts were perfused with 2 mM saxagliptin for 30 min followed by washout for 30 min. In an alternative approach, hearts were subjected to (global) ischemia/reperfusion (I/R) for 40/30 min, respectively, followed by perfusion with KrebsHenseleit solution alone (rundown) or containing 2 mM saxagliptin for 30 min. The following cardiac parameters were monitored and recorded by LabChart 7.2.5 (ADInstruments Ltd, Oxford, UK) in unpaced hearts: LV pressure, heart rate, perfusion pressure and ECG. Analysis of LV end-systolic pressure (LVESP), LV enddiastolic pressure (LVEDP), LV developed pressure and the rate of LV pressure rise (dP/dt max )/LV pressure fall (dP/dt min ) was performed (from at least 250 consecutive contractions) using blood pressure analysis module of LabChart 7.0 (ADInstruments Ltd). Heart rate and QTc interval (according to Bazett's formula) were analyzed (from at least 150 consecutive beats) using ECG module of LabChart 7.0.
Isolation of primary guinea pig ventricular cardiomyocytes
Guinea pigs were euthanized (40 mg/kg ketamine and 10 mg/kg xylazine), hearts were quickly removed, mounted on a Langendorff apparatus and the coronary system was perfused with a buffer (composition in mM: NaCl 126, KCl 4.7, KH 2 PO 4 1.2, MgSO 4 2.5, NaHCO 3 adjusted with NaOH) containing 2 mM pyruvic acid, 1 mg/ml bovine serum albumin and 100 IU/ml collagenase (Worthington CLS 2, Worthington Biochemical Corporation, NJ, USA) at 37°C, as previously described [24] . After enzymatic digestion, cardiomyocytes were isolated from ventricles and Ca 2+ concentration was raised stepwise to 1.8 mM. Cells were transferred to cell culture medium M199 containing 50 IU/ml penicillin and 50 mg/ml streptomycin, and maintained at 37°C under 5% CO 2 . All experiments were performed on the day after isolation.
Electrophysiological recordings and analysis
Action potentials (APs) and transmembrane currents were recorded in the whole cell configuration of the patch clamp technique using the amplifiers List L/M-EPC 7 (LIST Electronics, Darmstadt, Germany) and Axopatch 200B (Molecular Devices, CA, USA), and the A/D -D/A converters Digidata 1322A and Digidata 1200 (Molecular Devices) [25] . Patch pipettes with a tip-resistance of 2-3 MX were used. The pCLAMP software (Molecular Devices) was used for data acquisition and analyses. Only quiescent rodshaped cardiomyocytes with clear cross-striations were used for electrophysiological experiments. Cell membrane capacitance was determined by integration of the capacitive transient elicited by a 10 mV hyperpolarizing step from À50 mV. Ion currents were normalized to cell membrane capacitance and expressed as pA/pF. In order to allow equilibration of pipette solution with the cytosol, current recordings were started 4 min after rupture of the membrane patch. All ion currents and APs were recorded at 36-37°C. À8 M). For AP recordings cells were stimulated with minimal suprathreshold current pulses (5 ms) at a frequency of 1 Hz, as previously described [26] . In order to exclude any initial transient behaviour, first 10 APs were excluded from analysis. The pClamp data were imported into MATLAB Ò (R2016 a) and the AP parameters of 10 consecutive APs were algorithmically analyzed and averaged. I ss recordings were performed using voltage ramps from À100 to +60 mV (20 s duration).
In order to study L-type Ca 2+ current (I Ca,L ) without contamination of Na + current (I Na ) a 50-ms prepulse to À40 mV from a holding potential of À80 mV was used to inactivate I Na , as previously described [27] . K + currents were suppressed by substituting K + with Cs + ions in both, the standard external and internal solutions.
I Ca,L was elicited by a train of voltage pulses from À40 to +90 mV (10 mV interval, 400 ms) and the current amplitude was calculated as the difference between the peak inward current and the current at the end of the pulse [28] .
To calculate I Ca,L conductance (g Ca,L ), peak values of I Ca,L were divided by the driving force. I Ca,L reversal potential was not significantly different between control and treated cardiomyocytes and the mean value amounted +54 mV. For determination of steadystate activation curves, conductance values were normalized to the highest value and fitted according to the Boltzmann function
where V is the membrane potential, V 1=2act is the membrane potential of half maximum activation and k is the slope of the activation curve.
For the determination of steady-state inactivation, I Ca,L was activated with test pulses to +10 mV (400 ms), which were preceded by conditioning prepulses from À45 to +50 mV (5 mV increment, 400 ms). The amplitude of I Ca,L elicited by the test pulse was normalized to the highest value and plotted as a function of prepulse potential. Steady-state inactivation curves were fitted according to the Boltzmann function
where V is the membrane potential, V 1=2inact is the membrane potential of half maximum inactivation and k is the slope of the inactivation curve. For the measurement of delayed rectifier K + current (I K ), 0.25 mM CdCl 2 was added to standard external solution in order to eliminate Ca 2+ currents. To measure I K , membrane potential was depolarized by pre-pulses from a holding potential of À40 mV to +80 mV (5 s duration, 10 mV increment) followed by repolarizing pulses to À40 mV (5 s duration). For determination of current-voltage relation of I K , amplitudes of I K tail currents, elicited by repolarizing pulses to À40 mV, were calculated as the difference between peak tail current and the current at the end of the pulse (I K,tail ) and plotted against pre-pulse potentials. For determination of steady-state activation of I K , amplitudes of I K,tail were normalized to the highest value. Steady-state activation curves were fitted according to the Boltzmann function
Ca 2+ transient (CaT) measurements
Guinea pig ventricular cardiomyocytes were washed twice with the standard external solution and incubated with standard external solution containing 1 mM Fura-2-AM and 1 mM Pluronic F-127 (both Invitrogen, Lofer, Austria) for 30 min at 37°C. Fura-2-AM has been reported to have linear relationship between its fluorescence and intracellular Ca 2+ levels. The fluorescence ratio has been used to estimate relative changes in intracellular [Ca 2+ ] [29, 30] . CaT was assessed by field stimulation (platinum electrode distance: 1 cm; pulse duration: 5 ms; superathreshold pulse amplitude: 4 V/cm) on an inverted microscope (Olympus IX71, Olympus, Vienna, Austria) using Live Acquisition 2.5 software (FEI, Oregon, USA) at 37°C. Cardiomyocytes were excited alternately at 340 and 380 nm via Oligochrome (FEI) and fluorescent images were captured at 510 nm via ORCA-03G digital CCD camera (Hamamatsu Photonics, Herrsching, Germany). After 30 s recording without stimulation, cells were stimulated at a frequency of 0.5 Hz for 5 min. The F340/F380 ratio (an average of consecutive 15 contractions) was used as an index of cytosolic Ca 30 mM caffeine (without stimulation) and the amplitude of caffeine-evoked CaT was analyzed. Decay tau was analyzed using exponential fit from peak to baseline. Data were analyzed using Clampfit 10.2 and OriginPro 2015.
Fluorescence microscopy using fluorescamine-labelled saxagliptin
Fluorescamine (50 mg/ml in acetone) and saxagliptin were mixed in borate buffer (pH 8.5) at indicated concentrations at 25°C. The reaction mixture was evaporated to dryness and dissolved in the standard external solution. Cardiomyocytes were incubated with saxagliptin-fluorescamine adduct for 4 min and washed with the standard external solution on an inverted microscope (Olympus IX71) at 37°C. Fluorescence images were captured at excitation/emission wavelengths of 390/470 nm via ORCA-03 G digital CCD camera.
Quantification of cell-associated saxagliptin via HPLC analysis
HPLC analysis of saxagliptin was performed by derivatization with fluorescamine, as previously described [31] . HL-1 cells were washed three times with the standard external solution and lysed in ice-cold lysis buffer (composition in mM: 50 HEPES, 150 NaCl, 1 Table 2 Parameters of guinea pig heart, human right atrial appendage trabeculae and guinea pig ventricular cardiomyocyte function in response to saxagliptin treatment.
Parameter
Control Saxagliptin
Perfusion pressure (guinea pig heart) 59. . Extraction of saxagliptin from cell lysates (100 ml) was performed using 3 ml hexane/propanol (2:1, v/v) with gentle mixing for 5 min followed by centrifugation (2800 rpm, 3 min, 25°C). The organic layer was separated and dried under a gentle stream of N 2 . The residues were resuspended in 1 ml H 2 O, 500 ml borate buffer (pH 8.5) and 500 ml fluorescamine (1 mg/ml in acetone). After mixing for 30 s, 20 ml sample was subjected to HPLC analysis using a system consisting of a Waters 717 plus autosampler (Waters, MA, USA), a Shimadzu LC 20AD pump (Shimadzu, Duisburg, Germany) and a Waters 474 fluorescence detector (excitation/emission at 378/463 nm). Isocratic separation was performed on a Zorbax CN column (250 Â 4.6 mm, 5 lm particle size, Agilent, CA, USA) equipped with a guard column using (60:40) Acetonitrile:NaH 2 PO 4 (pH 2.7, 5 mM) as mobile phase (0.5 ml/min). All standard and sample values were subtracted with the blank control values and saxagliptin concentrations in samples were calculated by interpolation from a standard curve. Protein estimations of cell lysates were performed using BCA protein assay kit (Thermo Fischer Scientific, IL, USA) and used to normalize cell associated saxagliptin concentration.
Western blot analysis
Western blot analysis was performed as previously described [32] . Briefly, cells and tissues were lysed in 100 ml of ice-cold lysis buffer (as mentioned in HPLC) containing Halt TM Protease and Phosphatase Inhibitor Cocktail (1Â, Thermo Fischer Scientific). Protein lysates were centrifuged at 10,000 rpm (4°C, 10 min) to pellet debris. Protein estimation of cell lysates was performed using BCA protein assay kit (Thermo Fischer Scientific). Fifty mg of total protein was added to 10 ml of 4Â NuPAGE LDS sample buffer (Invitrogen) containing 2 ml sample reducing agent (Invitrogen) and heated (70°C, 10 min). Proteins were separated by electrophoresis on NuPAGE 4-12% Bis-Tris gel (Invitrogen) and transferred to nitrocellulose membranes (Invitrogen). Membranes were blocked with 5% (w/v) non-fat milk in TBST (Tris-buffered saline containing Tween 20) (25°C, 2 h) and incubated with primary antibodies (overnight at 4°C). The following primary antibodies were used (diluted in 5% [w/v] BSA-TBST): rabbit anti-DPP-4 antibody (1:500, Aviva System Biology-ARP63319_P050, 88 kDa), rabbit anti-phospho Ca 2+ / calmodulin-dependent protein kinase II (pCaMKII, T 286 , 1:1000, Abcam-ab32678, 56 kDa), rabbit anti-phospho-phospholamban 
Immunohistochemistry
Mouse hearts were snap frozen in liquid nitrogen and cut in serial sections of 5 mm thickness. Cytospins were prepared from guinea pig ventricular cardiomyocytes and HL-1 cardiomyocytes were cultured on glass-slides. All slides were stored at À20°C until use. After fixing in acetone for 5 min, slides were re-hydrated in PBS (pH 7.4) followed by blocking with UV ultra-block (Thermo Fischer Scientific) for 10 min. Afterwards slides were incubated with rabbit anti-DPP-4 antibody (Aviva System Biology-ARP63319_P050, CA, USA) diluted in antibody diluent (Dako, observed on a microscope (Leica CM 6000B, Leica Microsystem, Vienna, Austria) and images were captured using an Olympus DP72 camera.
RNA isolation and quantitative real-time PCR (qPCR)
For RNA isolation QIAshredder and RNeasy Mini Kit (Qiagen, Hilden, Germany) were used. After estimating RNA concentration, one lg RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. For gene quantification, six ng cDNA per template was used with GoTaq qPCR Master Mix (Promega, Vienna, Austria) and gene specific primers (Qiagen) for DPP-4 and GAPDH. The qPCR protocol was performed by LightCycler 480 system (Roche Diagnostics, Vienna, Austria). Relative gene expression levels were normalized to GAPDH and calculated using DDCT method [32] .
Statistics
Statistical analysis was performed using IBM SPSS Statistics 22. Approximate normal distribution of data was assessed by visual (histograms and normal Q-Q plots) and numerical (z-value of skewness and kurtosis; p value of Shapiro-Wilk test) investigation. Within group comparisons were performed by either paired Student's t-test or one-way repeated-measure ANOVA followed by Bonferroni's post-hoc test (sphericity was checked by Mauchly's test). After checking homogeneity of variance by Levene's test, between group comparisons were evaluated by unpaired Student's t-test, one-way ANOVA (followed by Tukey's post-hoc test) or ANCOVA to compare the effect of saxagliptin versus rundown by adjusting the matched control values (covariates). ANCOVA was only applied when covariates and regression slopes were not different between the compared groups. All tests were two-tailed and p values <0.05 were considered significant. All values are expressed as mean ± SEM. Rundown/saxagliptin data of individual hearts from Langendorff perfusion experiments are given for the comparative purpose. 'n' represents number of experiments or animals or guinea pig ventricular cardiomyocytes/animals or trabeculae/patients or HL-1 cardiomyocytes.
Results
Saxagliptin directly and reversibly impairs cardiac contractility
We assessed the acute effects of saxagliptin on contractility of human RAA trabeculae. Perfusion with cumulative doses of saxagliptin (0.6-2000 nM) significantly reduced RAA trabeculae developed force (Fig. 1A) ; a significant negative inotropic effect was observed starting from 60 nM, a dose comparable to the IC 50 of saxagliptin for DPP-4 inhibition (26-50 nM) [33, 34] .
Next, to elicit the observed acute effect within minutes on an organ level and to assess underlying mechanism(s), we resorted to a high dose (2 mM, Fig. 1A ) of saxagliptin for further experiments. Perfusion of isolated guinea pig hearts with saxagliptin (30 min) decreased left ventricular developed pressure (Fig. 1B) . This effect was partially reversed upon 30 min washout (Fig. 1C) . To evaluate role of Ca 2+ -homeostasis in the observed effect, CaT was measured in isolated guinea pig ventricular cardiomyocytes. Saxagliptin (1 h incubation) significantly reduced the amplitude of CaT (Fig. 1D) . In Fig. 1E , the CaT recordings show that saxagliptin produced a significant increase in end-diastolic calcium with a little change in peak systolic calcium. This could reflect impaired sequestration of calcium by the sarcoplasmic reticulum (SR). This impairment of calcium homeostasis might explain the reduction of contractile force described below, even though the peak systolic calcium level appears to be unchanged.
Saxagliptin internalizes into cardiomyocytes devoid of DPP-4
Since saxagliptin primarily targets DPP-4, we examined expression and localization of DPP-4 in cardiac myocytes/tissues. At mRNA level, DPP-4 expression was not detectable in cardiomyocytes (HL-1, a murine atrial cardiomyocyte cell line), while mouse LV showed a lower expression compared to ileum (Fig. 2A) . Western blot showed lack of DPP-4 expression in cardiac myocytes/tissues (mouse, human and guinea pig) where ileums (which do have DPP-4) served as positive controls (Fig. 2B ). In addition, immunohistochemistry revealed absence of DPP-4 in cardiomyocytes (guinea pig ventricular/HL-1, Fig. 2C ). Conversely, DPP-4 staining was observed in capillary endothelium of mouse LV (Fig. 2D , left panel; right panel represents negative control), the data are in line with previous observations in human and rat hearts [35] . However, capillary DPP-4 inhibition does not adequately explain the observed effects of saxagliptin on LV developed pressure (Fig. 1C) , since perfusion pressure of guinea pig hearts (a measure of coronary artery function) was unaffected ( Table 2 ) and saxagliptin reduced cytoplasmic CaT amplitude in isolated cardiomyocytes (Fig. 1D) . From these data, we conclude that saxagliptin impairs cardiac contractility in a DPP-4-independent manner. Next, we examined if saxagliptin directly associates with cardiomyocytes. HL-1 cardiomyocytes were incubated with a high concentration of saxagliptin (50 mM) for adequate HPLC detection. Fig. 2E shows the presence of saxagliptin in whole cell lysates, revealing association of saxagliptin with cardiomyocytes. To further elucidate cellular localization, saxagliptin was labeled with fluorescamine, a non-fluorescent dye that reacts with primary amines in 1:1 stoichiometry to yield fluorescence. Incubation of HL-1 cardiomyocytes with saxagliptin (2 mM)-fluorescamine (2 mM) adduct showed pronounced fluorescence in the cytosol but neither in the nucleus nor on the plasma membrane (Fig. 3Aiii) . In contrast, incubation with fluorescamine alone did not alter cellular fluorescence (Fig. 3Aii) compared to controls (Fig. 3Ai) , since unbound fluorescamine gets rapidly hydrolyzed in aqueous solution (half-life: 5-10 s) [36] . To verify internalization of unbound drug, fluorescamine (2 mM) was added to a 10-fold excess of saxagliptin (20 mM) . Under these conditions, cytosolic fluorescence was significantly reduced (Fig. 3Aiv) , suggesting competitive internalization of fluorescamine-bound versus unbound saxagliptin. Fluorescence intensity analysis is given in Fig. 3B. 
Saxagliptin impairs cardiac relaxation via inhibition of Ca
2+
reuptake by the sarcoplasmic reticulum and Ca 2+ extrusion by sodium/calcium exchange
In addition to reduced contractile force (Fig. 1) , saxagliptin impaired cardiac relaxation, manifested by a reduced rate of dP/ dt min of guinea pig hearts (Fig. 4A , washout is shown in Fig. 4B ), a reduced rate of %dF/dt min of human RAA trabeculae (Fig. 4C ) and increased CaT decay tau (s CaT ) of guinea pig ventricular cardiomyocytes (Fig. 4D) [37] . Therefore, we assessed contribution of SERCA2a and NCX1 to cardiomyocyte relaxation. Cardiomyocytes were superfused with 30 mM caffeine, a ryanodine receptor-2 agonist, which releases the majority of Ca 2+ from the SR to the cytoplasm [38, 39] . In this setting, $93% of Ca 2+ gets extruded from cytoplasm by NCX1 during caffeine-evoked CaT decay [40] . Therefore, reciprocal of caffeine-evoked CaT decay tau (s caffeine ) was analyzed to estimate fractional contribution of NCX1 in cardiac relaxation. Fig. 4E shows that saxagliptin reduced NCX1 function in Ca 2+ extrusion during cardiomyocyte relaxation.
Next, to estimate contribution of SERCA2a in SR Ca 2+ reuptake,
was subtracted from s CaT À1 of the same cardiomyocyte, as previously described [41] . Saxagliptin reduced SERCA2a function by $50% (Fig. 4F ) in SR Ca 2+ reuptake during cardiac relaxation.
Phospholamban (PLB) is an inhibitor of SERCA2a in its unphosphorylated form but inhibition is relieved upon phosphorylation of the protein by protein kinase A or CaMKII [42] . Therefore, we checked the effect of saxagliptin on PLB phosphorylation. In HL-1 cardiomyocytes, saxagliptin significantly reduced PLB phosphorylation (T   17 but not S 16 residue) starting from 15 min (Fig. 5A/B ) and 200 nM (Fig. 5C ). Since CaMKII phosphorylates PLB at T 17 residue [43] , we next determined CaMKII phosphorylation at the auto-regulatory T 286 residue. Saxagliptin significantly reduced CaMKII phosphorylation starting from 2.5 min (Fig. 5D ) and 200 nM (Fig. 5E) . Total PLB and CaMKII expression remained unchanged (Fig. 5F , densitometric evaluation is not shown). These results confirm that a reduced cytosolic Ca 2+ removal due to a compromised SERCA2a and NCX1 function contributes to the saxagliptin induced impairment of cardiac relaxation.
Saxagliptin induces LV systolic and diastolic dysfunction
Since saxagliptin impaired LV developed pressure (Fig. 1B) , we further analyzed LV end-systolic/diastolic pressure (LVESP and LVEDP). Saxagliptin significantly reduced LVESP (Fig. 6A) . Next, we examined if reduced Ca 2+ entry via L-type Ca 2+ channel and/ or its amount released from SR might contribute to this effect. I Ca,L density (Fig. 6B/C ) and steady-state activation/inactivation parameters of I Ca,L (Fig. 6D /E and Table 2 ) were unaffected by acute (5 min) and chronic (4-8 h) treatment of guinea pig ventricular cardiomyocytes with saxagliptin (only acute effects are shown).
On the other hand, saxagliptin reduced SR Ca 2+ content, evident by decreased caffeine-evoked CaT amplitude (Fig. 7A ). In parallel, we checked if the upstroke phase of contraction was affected. Saxagliptin did not alter the rate of dP/dt max in guinea pig left ventricle (Table 2) . Moreover, the rate of dF/dt max in human RAA trabeculae was also unaffected (Table 2 ). These data are consistent with the hypothesis that saxagliptin-induces negative inotropic effect via reduction in SR Ca 2+ content. saxagliptin by (A and C) ANCOVA and (B) one-way repeated-measure ANOVA followed by Bonferroni's post-hoc test.
In line with saxagliptin-reduced SERCA2a and NCX1 function in cytoplasmic Ca 2+ removal (Fig. 4E/F) , we observed increase in diastolic Ca 2+ levels in guinea pig ventricular cardiomyocytes (Fig. 7B) and elevation of LVEDP in guinea pig hearts (Fig. 7C , washout is shown in Fig. 7D ). These data reveal that saxagliptin induces diastolic dysfunction.
Saxagliptin prolongs QTc interval via inhibition of PKC-mediated I K density
As saxagliptin impaired cardiac excitation-contraction coupling (Figs. 1, 4, 6 and 7) , we further explored cardiac electrophysiology. ECG analysis revealed prolongation of QTc interval by saxagliptin perfusion (Fig. 8A , washout is shown in Fig. 8B ), though heart rate was unaffected (Table 2 ). Since the T-wave of an ECG represents ventricular repolarization [44] , we investigated AP duration of guinea pig ventricular cardiomyocytes. As expected, saxagliptin significantly prolonged AP duration at indicated repolarization levels (Fig. 8C/D) .
To elucidate whether repolarizing K + currents account for the observed AP duration prolongation, first slow voltage ramps (20 s) were analyzed to measure the steady state current (I ss ). Saxagliptin decreased the quasi steady-state current density to voltage relationship of I ss between +10 and +60 mV membrane potentials (Fig. 9A/B ) compared to rundown. This might be due to a reduction of the delayed rectifier potassium current I K which mainly underlies outward I ss and is responsible for the AP repolarisation and hence QTc interval in guinea pig ventricle [45] . Therefore, we determined I K density in guinea pig ventricular cardiomyocytes.
Saxagliptin significantly reduced I K current density compared to rundown from +30 to +80 mV membrane potentials (Fig. 9C/D) , while steady-state activation parameters of I K were unaffected ( Fig. 9E and Table 2 ). As PKC is a key regulator of I K [46] , activity of total PKC was measured. Saxagliptin reduced active PKC levels in HL-1 cardiomyocytes starting from 2.5 min (Fig. 10A ) and 1 mM (Fig. 10B) . This effect was also observed in human RAA (Fig. 10C) . Since phorbol 12,13-dibutyrate (PDB, 10 nM), a PKC activator, increases I K in ventricular cardiomyocytes [46] , we examined if PDB reverses saxagliptin-prolonged AP duration. Indeed, PDB completely reversed saxagliptin-induced AP duration prolongation at the tested repolarization levels (Fig. 10D) . These results suggest that saxagliptin prolongs QTc interval and AP duration by reducing PKC-mediated I K density.
Saxagliptin aggravates cardiac dysfunction induced by I/R injury
Ischemic heart disease is the major contributor to HF in subjects with diabetes [47] . Therefore, to mimic clinically prevalent and relevant condition of cardiac dysfunction, as evident in HF, guinea pig hearts were subjected to I/R injury. I/R injury significantly reduced LV developed pressure (Fig. 11A) . However, during and after the 30 min reperfusion period, we observed high variability in the amplitude and time-course of recovery of LV developed pressure amongst different guinea pig hearts. This is the most likely reason for no statistically significant difference for LVESP (Fig. 11B ) and LV developed pressure (Fig. 11A ) after saxagliptin perfusion in I/R injured hearts. Notably, saxagliptin treatment post-I/R further aggravated cardiac dysfunction, evident by elevation of LVEDP, reduction of dP/dt min and prolongation of QTc interval (Fig. 11C-E) . These data suggest that saxagliptin worsens pre-existing cardiac dysfunction.
Discussion
This is the first study to shed light upon a direct DPP-4-independent impact of saxagliptin on cardiac contractility and electrophysiology (Fig. 12) . Our data provide a mechanistic framework for saxagliptin-induced LV systolic and diastolic dysfunction, experimentally supporting clinical evidence of cardiac adverse events [17, 48] . Unexpectedly, we observed internalization of saxagliptin into cardiomyocytes. At the cellular level, saxagliptin inhibited CaMKII-mediated PLB phosphorylation that in turn reduced SERCA2a function in SR Ca 2+ reuptake. Subsequently, we observed a loss of SR Ca 2+ content, reduced CaT amplitude, diastolic Ca 2+ overload and impaired relaxation (Fig. 12) properties that lead to contractile dysfunction and increase the propensity for arrhythmia [50] . Out of the known candidates, multifunctional protein kinases contributing to the development of HF, CaMKII [51] as well as PKC [52] are strongly affected by saxagliptin. Loss of CaMKII auto-phosphorylation impairs PLB-mediated SERCA2a function in SR Ca 2+ reuptake during cardiac relaxation [42, 43] . Reduced SERCA2a expression [53] and/or its activity [54, 55] play a major role in the initiation and progression of HF [56] . This phenomenon reduces SR Ca 2+ content, lowers the amount of Ca 2+ released during cardiomyocyte contraction, decreases CaT amplitude in cardiomyocytes and thereby leads to systolic dysfunction at organ level [57, 58] . On the other hand, impaired SERCA2a function reduces the amount and rate of Ca 2+ removal from cytoplasm, hence elevating diastolic Ca 2+ levels, a key trigger for diastolic dysfunction [59] . However, the role of ryanodine receptors in saxagliptin-induced contractile dysfunction still remains to be studied. In addition to SERCA2a, NCX1 also plays a pivotal role in the maintenance of cardiac relaxation as well as diastolic Ca 2+ levels [60, 61] . Activity of SERCA2a and PLB decreases while that of NCX1 increases in failing human hearts [62, 63] . Increased NCX1 function protects the failing heart against diastolic dysfunction by promoting extrusion of cytosolic Ca
2+
. In line, an inverse relationship between NCX1 expression and the severity of diastolic dysfunction was observed in end-stage failing human hearts [64] . Our results show that saxagliptin impairs NCX1 function in Ca 2+ extrusion (estimated via analysis of the s caffeine ) during cardiac relaxation, yet the underlying mechanism(s) remain to be discovered. Therefore it is reasonable that along with reduced SERCA2a function, saxagliptin-impaired NCX1 function further slowed cardiac relaxation and contributed to diastolic Ca 2+ overload leading to diastolic dysfunction. HF is mostly associated with LV systolic dysfunction except for the patients with preserved ejection fraction. However, approximately 30-40% of patients suffer from impaired LV diastolic function that leads to reduced ejection fraction in about half of these patients [65] . Our data clearly demonstrate that saxagliptin intensified pre-existing cardiac dysfunction induced by I/R injury. In this setting, impaired relaxation, diastolic dysfunction and QTc interval prolongation were aggravated by saxagliptin perfusion. These results imply that saxagliptin adversely affects hearts with normal as well as reduced contractility, although these effects may be critical for hearts with pre-existing contractile dysfunction, as evident in HF. This notion supports clinical outcome where the highest rate of hospitalization for HF was observed in saxagliptin-treated patients suffering from HF [48] .
Our data demonstrate that saxagliptin prolongs AP duration in cardiomyocytes and thereby increases QTc interval, which are the most common electrophysiological abnormalities observed in the failing heart [11] . At molecular level, saxagliptin reduced PKC activity that lead to impairment of I K , yet the upstream signaling and involvement of specific PKC isoform(s) remain unknown. The role of PKC during myocardial ischemia has been well established in various experimental models [66] . In isolated rabbit hearts, inhibition of PKC activity was reported to impair post-ischemic myocardial recovery [67] . These observations indicate that saxagliptin-induced PKC inhibition might aggravate myocardial I/ R injury. PKC is known to intricately regulate cardiac stress signaling, including repolarizing K + currents [46] and signals associated with HF [52, 68] . On the other hand, reduced I K density underlies prolongation of AP duration, a key mechanistic link between HF and long-QT interval [69, 70] . AP duration prolongation directly increases CaT amplitude [71] by two distinct mechanisms including enhanced Ca 2+ entry via L-type Ca 2+ channels [72] and reduced Ca 2+ extrusion via NCX1 [73] . These processes may partially compensate saxagliptin-reduced LVESP and in turn LV developed pressure. Currently, limited information is available on saxagliptinmediated effects on QT interval in patients. Safety and pharmacokinetic study based on two small trials consisting 40 healthy volunteers and 50 patients exposed to various doses of saxagliptin for two weeks showed no significant impact on QTc interval [74] . Moreover, within the SAVOR-TIMI-53 trial, no follow-up ECGs were performed after saxagliptin administration [17] . On the other hand, sitagliptin [75] and linagliptin [76] showed no significant effect on QT interval during clinical studies. Conversely, teneligliptin was associated with QTc interval prolongation at high doses [77] . This would be consistent with our data showing inhibition of PKC at high concentrations (1-2 mM) of saxagliptin that lead to prolongation of AP duration and thereby QTc interval. Particularly, for patients at the risk of accumulation of saxagliptin (such as patients with renal failure [78] ), monitoring of QTc interval may be prudent. Currently available pharmacokinetic data suggest poor membrane permeability of saxagliptin and its metabolite 5-hydroxysaxagliptin due to their hydrophilic nature [14] . Our data reveal high intrinsic permeability of saxagliptin through cardiomyocyte membrane in-vitro, albeit the exact transport mechanism is yet to be discovered. Since cardiomyocytes lack DPP-4, these observations suggest that saxagliptin affects cardiac function in a DPP-4-independent manner and via association with and internalization into cardiomyocytes. However, one cannot exclude the effect of saxagliptin on endothelial DPP-4 in myocardium. DPP-4 inhibition with sitagliptin resulted in vasodilatation through increased nitric oxide production via GLP-1 [79] . Saxagliptin treatment increased aortic nitric oxide synthesis in obese Zucker rats. The effect was observed prior to the hypoglycemic action of the drug [80] . In the present study, we did not observe any change in coronary perfusion after acute saxagliptin treatment, indicating that the observed acute effects are DPP-4-independent.
To conclude, our novel data reveal acute and cardiomyocyte intrinsic deleterious actions of saxagliptin on cardiac function and support the outcome of the cardiovascular safety trial. The data obtained from human atrial trabeculae reveal that the effect of saxagliptin on cardiac function is independent of the presence of diabetes. Since the severity of cardiac dysfunction induced by saxagliptin is substantial, it warrants caution particularly for patients with heart or renal failure, as those patients had the highest increase in the rate of hospitalization for HF in the SAVOR-TIMI 53 trial [48] . Apart from the acute off-target adverse effects of saxagliptin presented in our study, other (in)direct mechanism(s) may contribute to long-term cardiac adverse effects of saxagliptin as observed in the SAVOR-TIMI 53 trial. This study only investigated the acute effects of saxagliptin and further studies are necessary to understand the effects of its chronic administration. Moreover, further in vivo studies including diabetes-induced HF model may provide additional confirmation for the off-target effects of saxagliptin on cardiac function. 
